Dyne Therapeutics (NASDAQ:DYN) Azioni

DYNE THERAPEUTICS INC

Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Dyne Therapeutics Inc

DYNASTAR HOLDINGS INC by Dynastar Holdings, Inc.

Dynastar Holdings Inc

Dye & Durham Ltd

DynTek, Inc. Com

iShares U.S. Equity Factor Rotation Active ETF

ETF Opportunities Trust Idx Dynamic Innovation Etf

DynaResource Inc

Dynatronics Corp

Dynamix Corporation - Class A Ordinary Share

Dynamix Corp

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.97) per share which met the analyst consensus estimate. This is a 38.57 percent decrease over losses of $(0.70) per share from the same period last year.

Earnings

News

Dyne Therapeutics Q2 EPS $(0.97), Inline

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Neutral and lowers the price target from $10 to $9.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $9

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell sharply in pre-market trading after CEO Elon Musk reignited political comeback rumors following his criticism of President Donald <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">Trump‘s spending bill</a>.
Late Monday, Musk expressed his disapproval of the spending bill on social media platform X, stating, "If this insane spending bill passes, the America Party will be formed the next day." He further criticized the existing political system, calling for alternative parties to give Americans a voice.
Tesla shares dipped 4.6% to $303.13 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) dipped 18.7% to $4.31 in pre-market trading after jumping 72% on Monday.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares fell 12.9% to $8.30 in pre-market trading after the company announced the pricing of $200.0 million public offering of common stock.</li>
<li>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) dipped 6.7% to $293.03 in pre-market trading.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) fell 6.6% to $59.70 in pre-market trading following second-quarter results.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) fell 5.5% to $269.20 in pre-market trading after the company announced a proposed $750 million common stock offering and $600 million in convertible senior notes due 2030 to repay debt and expand manufacturing.</li>
<li>New Found Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFGC#NYSE">NFGC</a>) fell 4.2% to $1.36 in pre-market trading.</li>
<li>IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) fell 4% to $14.00 in pre-market trading. IREN achieved mid-year target of 50 EH/s Installed Self-Mining Capacity</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVAV

GNLN

IREN

NFGC

PODD

PRGS

TSLA

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

Dyne Therapeutics shares are trading lower after the company announced a $200 million public offering.

Shares of Thumzup Media Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) rose sharply in today's pre-market trading after the company announced a $6.5 million <a href="https://www.benzinga.com/quote/TZUP">registered direct offering</a>.
Thumzup Media shares jumped 20.4% to $8.45 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) surged 238.7% to $10.60 in pre-market trading after gaining 12% on Monday.</li>
<li>Wolfspeed, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) gained 90.8% to $0.7639 in pre-market trading after the company initiated pre-packaged restructuring process with support of key lenders.</li>
<li>Prestige Wealth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) climbed 64.1% to $0.58 in pre-market trading.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) rose 41.2% to $0.2640 in pre-market trading after falling around 49% on Monday.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) gained 35.6% to $5.17 in pre-market trading after dipping over 5% on Monday.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) gained 14% to $0.89 in pre-market trading after falling 5% on Monday.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) surged 11.2% to $3.29 in pre-market trading after gaining 28% on Monday.</li>
<li>Jyong Biotech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) jumped 10.2% to $9.37 in pre-market trading. Jyong Biotech recently announced the closing of $20 million initial public offering.</li>
<li>BigBear.ai Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NASDAQ">BBAI</a>) gained 6.7% to $7.24 in pre-market trading after climbing over 16% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares tumbled 19.3% to $0.1865 in pre-market trading after jumping 120% on Monday.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) fell 19.1% to $0.0935 in pre-market trading. Globavend and Strawberrynet Cosmetics, on Monday, executed a strategic partnership.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) dipped 18.7% to $4.31 in pre-market trading after jumping 72% on Monday.</li>
<li>RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) dipped 18% to $2.46 in pre-market trading after falling 7% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) declined 17.3% to $1.15 in pre-market trading after gaining around 15% on Monday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) declined 17.2% to $4.20 in pre-market trading. Applied DNA recently conducted a 27% workforce reduction and ceased operations at Applied DNA Clinical Lab.</li>
<li>Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) fell 16.6% to $11.07in pre-market trading. Artelo Biosciences shares jumped 96% on Monday after the company announced data from its first-in-human study for ART26.12.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 14.5% to $2.89 in pre-market trading after gaining 93% on Monday.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares fell 12.9% to $8.30 in pre-market trading after the company announced the pricing of $200.0 million public offering of common stock.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) fell 6.6% to $59.70 in pre-market trading. Progress Software posted better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

APDN

ARBK

ARTL

BBAI

BGLC

DTCK

IPDN

MENS

MSPR

OGEN

SYTA

TZUP

WOLF

Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Reported Earlier, Dyne Therapeutics Prices $200M Public Offering Of 24,242,425 Common Shares At $8.25 Each

<h3>Gainers</h3>
<ul>
<li>Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) shares moved upwards by 14.2% to $0.73 during Monday's after-market session. The market value of their outstanding shares is at $57.0 million. </li>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) stock increased by 10.39% to $1.38. The market value of their outstanding shares is at $45.5 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares rose 8.61% to $0.86. The market value of their outstanding shares is at $40.8 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares moved upwards by 8.25% to $7.7. The market value of their outstanding shares is at $14.3 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares moved upwards by 7.8% to $0.35. The market value of their outstanding shares is at $13.8 million. </li>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 6.72% to $0.32. The market value of their outstanding shares is at $36.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 10.5% to $4.61 during Monday's after-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) shares fell 10.18% to $3.53. The company's market cap stands at $5.4 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares fell 8.62% to $8.7. The company's market cap stands at $1.0 billion. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) stock declined by 7.75% to $10.01. The market value of their outstanding shares is at $478.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares fell 7.01% to $1.46. The company's market cap stands at $5.5 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 6.78% to $0.23. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AXGN

CLRB

MLSS

MRSN

RLYB

STTK

TELO

VTAK

XBIO

12 Health Care Stocks Moving In Monday's After-Market Session

Dyne Therapeutics shares are trading lower after the company announced a proposed $200 million common stock offering.

Offerings

Dyne Therapeutics Announces Proposed Public Offering Of $200M Common Stock

Financing

HTGC

Dyne Therapeutics Enters $275M Debt Financing With Hercules Capital; $100M Upfront, $175M Tied To Milestones

Guggenheim analyst Debjit Chattopadhyay reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $50 price target.

Reiteration

Guggenheim Reiterates Buy on Dyne Therapeutics, Maintains $50 Price Target

Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Outperform and lowers the price target from $46 to $32.

Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $32

<h3>Gainers</h3>
<ul>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares rose 117.3% to $0.67 during Tuesday's regular session. The market value of their outstanding shares is at $15.6 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) stock rose 78.95% to $11.22. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 67.34% to $4.97. The company's market cap stands at $14.3 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 58.35% to $0.99. The company's market cap stands at $2.1 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock increased by 55.03% to $2.31. The market value of their outstanding shares is at $146.2 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares moved upwards by 26.67% to $0.23. The company's market cap stands at $20.0 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock declined by 27.6% to $0.24 during Tuesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares declined by 21.55% to $10.84. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 19.24% to $0.84. The company's market cap stands at $2.4 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares declined by 17.1% to $2.57. The company's market cap stands at $48.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 15.53% to $0.32. The company's market cap stands at $1.0 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 14.97% to $0.02. The market value of their outstanding shares is at $9.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

ADIL

BDRX

BMGL

EYEN

GALT

HCTI

HSDT

SLRX

VERV

XAIR

12 Health Care Stocks Moving In Tuesday's Intraday Session

Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock is trading lower after the company announced on Tuesday that it had revised the ongoing Registrational Expansion Cohort in the Phase 1/2 ACHIEVE trial for DYNE-101 for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
The primary endpoint is a change from baseline in middle finger myotonia as measured by vHOT at 6 months, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45968516/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-101-and-updated-plan-for" rel="noreferrer noopener">compared to placebo</a>.
<ul class="wp-block-list">
<li>Video hand opening time (vHOT) measures hand function and myotonia (delayed relaxation of skeletal muscles after voluntary contraction).</li>
</ul>
Secondary endpoints include change from baseline in splicing as measured by the composite alternative splicing index (CASI-22), muscle strength as assessed by Quantitative Muscle Testing (QMT), performance on both the 10-Meter Walk/Run Test (10MWR) and 5 Times Sit to Stand Test (5xSTS), and the Myotonic Dystrophy Health Index (MDHI) patient-reported outcome measure, all at 6 months compared to placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44441276/jpmorgan-seeks-clarity-on-dyne-therapeutics-dyne-101-expansion-regulatory-path" target="_blank" rel="noreferrer noopener">JPMorgan Seeks Clarity On Dyne Therapeutics&#8217; DYNE-101 Expansion, Regulatory Path</a>
The cohort is expected to enroll 60 participants, randomized 3:1 to receive DYNE-101 6.8 mg/kg Q8W or placebo. Dyne plans to complete enrollment in the Registrational Expansion Cohort in the fourth quarter of 2025.
Dyne intends to use data from the Registrational Expansion Cohort and the already enrolled patients in the multiple ascending dose (MAD) and ongoing long-term extension portions of the ACHIEVE trial to support a potential submission for Accelerated Approval in the U.S.
Data from the cohort are planned for mid-2026 to support a potential U.S. Accelerated Approval submission in late 2026.
It seems that the company&#8217;s stock plunged as earlier Dyne expected to submit an Accelerated Approval Biologics License Application (BLA) in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45281892/dyne-therapeutics-reports-first-quarter-2025-financial-results-and-recent-business-highlights" rel="noreferrer noopener">the first half of 2026</a>.
Dyne plans to initiate a confirmatory Phase 3 clinical trial in Q1 2026.
Dyne also reported new long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled MAD portion of the DYNE-101 ACHIEVE trial, including data from the 6.8 mg/kg Q8W cohort (n=6) at up to 12 months.
At the registrational dose of 6.8 mg/kg Q8W, DYNE-101 demonstrated robust and sustained improvement in myotonia as measured by vHOT and sustained improvements across multiple other endpoints.
<ul class="wp-block-list">
<li>As previously disclosed, treatment with DYNE-101 led to an improvement in vHOT of 3.3 seconds compared to placebo at 6 months.</li>
<li>New data demonstrated that mean improvements at 6 months were sustained at 12 months for vHOT, 10MWR, 5xSTS, MDHI, and QMT, which demonstrated a 10% improvement in strength at 6 months, increasing to 20% at 12 months relative to baseline.</li>
</ul>
The company expects that its $677.5 million cash, cash equivalents, and marketable securities as of March 31, 2025, will be sufficient to fund its operations into the fourth quarter of 2026.
The U.S. Food and Drug Administration (FDA) on Tuesday granted Breakthrough Therapy Designation to DYNE-101 for DM1.
Price Action: DYN stock is trading lower by 18.2% to $11.30 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45844751/avidity-biosciences-touts-encouraging-functional-gains-and-biomarker-reductions-in-rare-muscular-weakness-disease-trial" target="_blank" rel="noreferrer noopener">Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

General

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?

Dyne Therapeutics shares are trading lower after the company announced it submitted revised ACHIEVE Trial protocol to the FDA, elevating vHOT to primary endpoint for DYNE-101 in DM1 with Accelerated Approval submission in late 2026 instead of H1 2026.

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $50 price target.

Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $50 Price Target

Dyne Submitted Revised ACHIEVE Trial Protocol To FDA, Elevating vHOT To Primary Endpoint For DYNE-101 In DM1; Data Planned For Mid 2026 To Support Potential Accelerated Approval Submission In Late 2026

<h3>Gainers</h3>
<ul>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock moved upwards by 235.5% to $1.03 during Tuesday's pre-market session. The company's market cap stands at $24.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares rose 82.37% to $1.14. The company's market cap stands at $2.4 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares moved upwards by 75.93% to $11.03. The company's market cap stands at $983.3 million. </li>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock increased by 38.35% to $0.37. The company's market cap stands at $6.1 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 34.0% to $0.45. The market value of their outstanding shares is at $18.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) shares increased by 16.66% to $1.75. The market value of their outstanding shares is at $229.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 34.8% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares decreased by 21.86% to $10.8. The company's market cap stands at $1.2 billion. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares declined by 20.66% to $0.6. The market value of their outstanding shares is at $72.1 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares decreased by 14.99% to $3.63. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 11.06% to $0.3. The market value of their outstanding shares is at $7.2 million. </li>
<li>Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) stock decreased by 9.8% to $20.9. The market value of their outstanding shares is at $2.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

CYCC

PRME

PRPH

SGRY

SNPX

UNCY

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Dyne Therapeutics Granted FDA Breakthrough Therapy Designation For DYNE-101

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 53.0% to $0.98 during Monday's after-market session. The company's market cap stands at $2.0 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares rose 12.15% to $15.5. The company's market cap stands at $1.7 billion. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares rose 8.59% to $4.8. The company's market cap stands at $43.1 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares increased by 8.02% to $3.5. The company's market cap stands at $677.6 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares moved upwards by 7.92% to $0.23. The company's market cap stands at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 6.3% to $6.58. The company's market cap stands at $179.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock fell 8.5% to $1.69 during Monday's after-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock declined by 8.34% to $1.21. The company's market cap stands at $18.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined by 7.86% to $0.35. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 7.22% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) stock fell 7.22% to $2.96. The market value of their outstanding shares is at $4.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 6.65% to $4.78. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

CLNN

CPHI

DHAI

GOVX

SSII

TCRT

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.  - DYN

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Comments

Dyne Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO